Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024

Savushkin/E+ via Getty Images Topline Summary and Update Poseida Therapeutics (NASDAQ:PSTX) is a cell-therapy-focused biotech that I covered with some optimism back in December 2023, with the company's pipeline showing early signs of being the real deal. In particular, I was interested in their "allogeneic" engineered cell therapy approach that appeared to dodge one of the most concerning complications of a non-self bone marrow transplant: graft-versus-host disease (GVHD). Today, I want to take another look ...